August 2022
Volume 11, Issue 8
Open Access
Erratum  |   August 2022
Erratum in: Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
Translational Vision Science & Technology August 2022, Vol.11, 15. doi:https://doi.org/10.1167/tvst.11.8.15
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erratum in: Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea. Trans. Vis. Sci. Tech. 2022;11(8):15. doi: https://doi.org/10.1167/tvst.11.8.15.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Erratum in: “Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea” by Jianfeng Yu, Pengfei Li, Zhuang Li, Yingqi Li, Jiawei Luo, Wenru Su, and Dan Liang (Transl Vis Sci Technol. 2022;11(3):34), https://doi.org/10.1167/tvst.11.3.34
After this article was published, the authors found an error in Figure 3C. They had placed the same flow result in both 3A and 3C. Figure 3C has now been corrected in the article online. Additionally, after checking all of the raw data carefully, the authors found the wrong anterior segment photography in the tofacitinib-treated group in Figure 1F. The photography was not included in the tofacitinib-treated group. Figure 1F has now been corrected. These changes do not affect the results and conclusions of the article. 
Original Figure 3 
Image not available 
Corrected Figure 3 
Image not available 
Original Figure 1 
Image not available 
Corrected Figure 1 
Image not available 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×